0 Comments
0 Shares
5K Views
0 Reviews
Search
Discover new people, create new connections and make new friends
-
Please log in to like, share and comment!
-
Singapore’s Nuevocor raises $45M Series B for Novel Cardiomyopathy therapy developmentNuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, has announced the successful completion of $45 million Series B financing. The round was co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund,...0 Comments 0 Shares 74 Views 0 Reviews
Sponsored